Compare TG Therapeutics Inc (TGTX) vs VICI Properties Inc (VICI) Price & Performance

TG Therapeutics (TGTX) trades at $54.96, up 3.8% with strong fundamentals including 82.37% gross margins and 100.28% ROE, though recent earnings misses and a negative cash flow of -$100.70M in 2025 raise concerns. Technical indicators show bearish momentum with support at $51-$52, while news highlights BRIUMVI's market share gains and potential acquisition interest.

The outlook remains mixed: analyst consensus is bullish with an $80.50 price target, but risks include ongoing litigation, earnings volatility, and competitive pressures. Upside potential hinges on BRIUMVI's continued growth and pipeline advancements, making TGTX a high-risk, high-reward biotech play.

VICI Properties trades at $22.83, up 0.84% today, with a bearish technical signal from moving averages. The stock shows strong fundamentals with a P/E of 8.83, net income margin of 67.5%, and robust cash flow from operations of $2.51B in 2025. Recent news highlights dividend coverage strength despite stock price declines, and the company expanded its tenant base with a new lease for Century Mile and Century Downs.

The outlook is mixed: analyst consensus is strongly bullish with a $28.90 price target, but risks include tenant concentration and rising Treasury yields. The stock offers value with a low P/E and high dividend yield, but investors should weigh the bearish technicals and macroeconomic pressures against the solid fundamental performance.